We are live on ! Find out more
SPRB

Spruce Biosciences

57 hedge funds and large institutions have $80.4M invested in Spruce Biosciences in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

967% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 3

367% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 3

78% more funds holding

Funds holding: 3257 (+25)

66% more capital invested

Capital invested by funds: $48.3M → $80.4M (+$32.1M)

0.19% more ownership

Funds ownership: 53.92%54.1% (+0.19%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
57
Holders Change
+25
Holders Change %
+78.13%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
32
Increased
14
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change

SPRB Hedge Fund Activity: Q2 2026 in Review

57 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2026, worth a combined $80.4M — up 66% from $48.3M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SPRB positions and 3 closed out — a net gain of 29 holders — while 14 added to existing stakes and 3 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $14M. The largest seller was Balyasny Asset Management, cutting an estimated $1.56M.

  • 57 institutional investors held Spruce Biosciences (SPRB) as of Q2 2026, up from 32 in Q1 2026.
  • Funds reported $80.4M of Spruce Biosciences stock for Q2 2026, up 66% quarter-over-quarter.
  • 32 funds opened new Spruce Biosciences positions in Q2 2026 and 3 closed out, a net change of +29 holders.
  • The largest Spruce Biosciences buyer in Q2 2026 was AIGH Capital Management, an estimated $14M added.
  • The largest Spruce Biosciences seller in Q2 2026 was Balyasny Asset Management, an estimated $1.56M sold.

Based on aggregated 13F filings for Q2 2026.